Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Address
155 BOVET RD., SUITE 303
SAN MATEO, CA 94402
Founded
2006
Number of Employees
10
Website
http://www.sagimet.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)